{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:21:16Z","timestamp":1782789676614,"version":"3.54.5"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology","doi-asserted-by":"publisher","award":["BT\/PR41246\/NER\/95\/1685\/2020"],"award-info":[{"award-number":["BT\/PR41246\/NER\/95\/1685\/2020"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.virol.2025.110477","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T02:45:01Z","timestamp":1740797101000},"page":"110477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Development of an apoptotic lentogenic Newcastle disease virus strain by incorporating the p30 protein of African swine fever virus"],"prefix":"10.1016","volume":"606","author":[{"given":"Nilave Ranjan","family":"Bora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2025.110477_bib1","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1128\/MCB.02014-06","article-title":"Deciphering the cross talk between hnRNP K and c-Src: the c-Src activation domain in hnRNP K is distinct from a second interaction site","volume":"27","author":"Adolph","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.virol.2025.110477_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01293-18","article-title":"A proteomic atlas of the african swine fever virus particle","volume":"92","author":"Alejo","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110477_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.20506\/rst.19.2.1231","article-title":"Newcastle disease and other avian paramyxoviruses","volume":"19","author":"Alexander","year":"2000","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.virol.2025.110477_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/713655022","article-title":"Gordon memorial lecture. Newcastle disease","volume":"42","author":"Alexander","year":"2001","journal-title":"Br. Poult. Sci."},{"key":"10.1016\/j.virol.2025.110477_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2014.02.009","article-title":"Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy","volume":"159","author":"Bai","year":"2014","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.virol.2025.110477_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11262-024-02072-9","article-title":"Spillover of Newcastle disease virus to Himalayan Griffon vulture: a possible food-based transmission","volume":"60","author":"Bhattacharya","year":"2024","journal-title":"Virus Genes"},{"key":"10.1016\/j.virol.2025.110477_bib7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V","article-title":"Newcastle disease virus as an antineoplastic agent","volume":"18","author":"Cassel","year":"1965","journal-title":"Cancer"},{"key":"10.1016\/j.virol.2025.110477_bib8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1089\/jir.2012.0095","article-title":"The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-beta signaling","volume":"33","author":"Ch'ng","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.virol.2025.110477_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.14218\/JCTH.2021.00284","article-title":"Oncolytic activity of wild-type newcastle disease virus HK84 against hepatocellular carcinoma associated with activation of type I interferon signaling","volume":"10","author":"Chen","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.virol.2025.110477_bib10","article-title":"Interaction network of African swine fever virus structural protein p30 with host proteins","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virol.2025.110477_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00256695","article-title":"Rapid chemosensitivity testing of human lung tumor cells using the MTT assay","volume":"17","author":"Cole","year":"1986","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.virol.2025.110477_bib12","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.281.17.1588-a","article-title":"Use of Newcastle disease virus vaccine (MTH-68\/H) in a patient with high-grade glioblastoma","volume":"281","author":"Csatary","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.virol.2025.110477_bib13","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1128\/JVI.00241-06","article-title":"Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death","volume":"80","author":"Elankumaran","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110477_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.virol.2025.110477_bib15","first-page":"125","article-title":"Induction of apoptosis by a Newcastle disease virus vaccine (MTH-68\/H) in PC12 rat phaeochromocytoma cells","volume":"21","author":"Fabian","year":"2001","journal-title":"Anticancer Res."},{"key":"10.1016\/j.virol.2025.110477_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.cdd.4400404","article-title":"The role of phosphatidylserine in recognition of apoptotic cells by phagocytes","volume":"5","author":"Fadok","year":"1998","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.virol.2025.110477_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ijc.21821","article-title":"Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence","volume":"119","author":"Fiola","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.virol.2025.110477_bib18","first-page":"840","article-title":"Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity","volume":"40","author":"Fournier","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.virol.2025.110477_bib19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","article-title":"Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme","volume":"13","author":"Freeman","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2025.110477_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","article-title":"Newcastle disease virus: current status and our understanding","volume":"184","author":"Ganar","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.virol.2025.110477_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/viro.1998.9068","article-title":"The African swine fever virus proteins p54 and p30 are involved in two distinct steps of virus attachment and both contribute to the antibody-mediated protective immune response","volume":"243","author":"Gomez-Puertas","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.virol.2025.110477_bib22","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1016\/j.febslet.2008.08.031","article-title":"African swine fever virus protein p30 interaction with heterogeneous nuclear ribonucleoprotein K (hnRNP-K) during infection","volume":"582","author":"Hernaez","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.virol.2025.110477_bib23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-06-1817","article-title":"An optimized clinical regimen for the oncolytic virus PV701","volume":"13","author":"Hotte","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.virol.2025.110477_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.canlet.2005.02.008","article-title":"The cytotoxic anti-tumor effect of MTH-68\/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitro","volume":"231","author":"Hrabak","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.virol.2025.110477_bib25","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ps\/82.6.899","article-title":"Recombinant Newcastle disease virus as a vaccine vector","volume":"82","author":"Huang","year":"2003","journal-title":"Poult. Sci."},{"key":"10.1016\/j.virol.2025.110477_bib26","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/sj.gt.3303026","article-title":"Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy","volume":"14","author":"Janke","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.virol.2025.110477_bib27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1515\/jvetres-2017-0017","article-title":"Roles of african swine fever virus structural proteins in viral infection","volume":"61","author":"Jia","year":"2017","journal-title":"J Vet Res"},{"key":"10.1016\/j.virol.2025.110477_bib28","first-page":"367","article-title":"Evaluation of apoptosis induction by newcastle disease virus LaSota strain in human breast carcinoma cells","volume":"75","author":"Kalantari","year":"2020","journal-title":"Arch Razi Inst"},{"key":"10.1016\/j.virol.2025.110477_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5483\/BMBRep.2008.41.2.158","article-title":"Hepatitis B virus X protein enhances NFkappaB activity through cooperating with VBP1","volume":"41","author":"Kim","year":"2008","journal-title":"BMB Rep"},{"key":"10.1016\/j.virol.2025.110477_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/viro.2000.0618","article-title":"Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation","volume":"278","author":"Krishnamurthy","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.virol.2025.110477_bib31","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s00705-019-04425-4","article-title":"Evaluation of surface glycoproteins of classical swine fever virus as immunogens and reagents for serological diagnosis of infections in pigs: a recombinant Newcastle disease virus approach","volume":"164","author":"Kumar","year":"2019","journal-title":"Arch. Virol."},{"key":"10.1016\/j.virol.2025.110477_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/cgt.2015.35","article-title":"Molecular characterization of an apoptotic strain of Newcastle disease virus isolated from an outbreak in India","volume":"22","author":"Kumar","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.virol.2025.110477_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1741-7015-10-25","article-title":"Advances in using PARP inhibitors to treat cancer","volume":"10","author":"Kummar","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.virol.2025.110477_bib34","article-title":"Safety and clinical usage of newcastle disease virus in cancer therapy","volume":"2011","author":"Lam","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.virol.2025.110477_bib35","first-page":"1177","article-title":"Paramyxoviridae: the viruses and their replication","author":"Lamb","year":"1996","journal-title":"Fields Virology"},{"key":"10.1016\/j.virol.2025.110477_bib36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3748\/wjg.v9.i3.495","article-title":"Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract","volume":"9","author":"Liang","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.virol.2025.110477_bib37","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/jnci\/80.16.1305","article-title":"Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity","volume":"80","author":"Lorence","year":"1988","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.virol.2025.110477_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47244-y","article-title":"Newcastle disease virus mediated apoptosis and migration inhibition of human oral cancer cells: a probable role of beta-catenin and matrix metalloproteinase-7","volume":"9","author":"Morla","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2025.110477_bib39","doi-asserted-by":"crossref","first-page":"109967","DOI":"10.1016\/j.virol.2023.109967","article-title":"The p30 protein of the African swine fever virus behaves as an RNase","volume":"590","author":"Nandy","year":"2024","journal-title":"Virology"},{"key":"10.1016\/j.virol.2025.110477_bib40","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.vaccine.2019.11.088","article-title":"Evaluation of Japanese encephalitis virus E and NS1 proteins immunogenicity using a recombinant Newcastle disease virus in mice","volume":"38","author":"Nath","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2025.110477_bib41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11033-024-09653-9","article-title":"The scaffold protein disabled 2 (DAB2) and its role in tumor development and progression","volume":"51","author":"Pandya","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.virol.2025.110477_bib42","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1128\/JVI.77.17.9522-9532.2003","article-title":"Newcastle disease virus V protein is a determinant of host range restriction","volume":"77","author":"Park","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110477_bib43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: the bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.virol.2025.110477_bib44","first-page":"947","article-title":"Tumor response and 4 year survival-data of patients with advanced renal-cell carcinoma treated with autologous tumor vaccine and subcutaneous R-IL-2 and IFN-alpha(2b)","volume":"6","author":"Pomer","year":"1995","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.virol.2025.110477_bib45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.virusres.2008.01.010","article-title":"Induction of apoptosis in Vero cells by Newcastle disease virus requires viral replication, de-novo protein synthesis and caspase activation","volume":"133","author":"Ravindra","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.virol.2025.110477_bib46","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/nprot.2006.238","article-title":"Analysis of apoptosis by propidium iodide staining and flow cytometry","volume":"1","author":"Riccardi","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.virol.2025.110477_bib47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.virusres.2012.10.025","article-title":"African swine fever virus controls the host transcription and cellular machinery of protein synthesis","volume":"173","author":"Sanchez","year":"2013","journal-title":"Virus Res."},{"key":"10.1016\/j.virol.2025.110477_bib48","first-page":"677","article-title":"Immunization with virus-modified tumor cells","volume":"25","author":"Schirrmacher","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.virol.2025.110477_bib49","first-page":"363","article-title":"Newcastle disease virus activates macrophages for anti-tumor activity","volume":"16","author":"Schirrmacher","year":"2000","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.virol.2025.110477_bib50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-1-59745-561-9_30","article-title":"Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer","volume":"542","author":"Schirrmacher","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.virol.2025.110477_bib51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.gt.3300787","article-title":"Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus","volume":"6","author":"Schirrmacher","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.virol.2025.110477_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111296","article-title":"The effects of the LaSota strain of oncolytic Newcastle disease virus vaccine on cervical intraepithelial neoplasia Patients-Clinical cohort study","volume":"126","author":"Sharifi","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.virol.2025.110477_bib53","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bbrc.2008.05.175","article-title":"hnRNP G elicits tumor-suppressive activity in part by upregulating the expression of Txnip","volume":"372","author":"Shin","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.virol.2025.110477_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6532(99)00072-4","article-title":"Newcastle disease virus (NDV): brief history of its oncolytic strains","volume":"16","author":"Sinkovics","year":"2000","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.virol.2025.110477_bib55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF01198099","article-title":"The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells","volume":"121","author":"Tzadok-David","year":"1995","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.virol.2025.110477_bib56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/8.4.491","article-title":"Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B","volume":"8","author":"Umansky","year":"1996","journal-title":"Int. Immunol."},{"key":"10.1016\/j.virol.2025.110477_bib57","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1158\/0008-5472.CAN-07-1025","article-title":"Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus","volume":"67","author":"Vigil","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2025.110477_bib58","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/jcp.29186","article-title":"The emerging roles of hnRNPK","volume":"235","author":"Wang","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.virol.2025.110477_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM196409242711302","article-title":"Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report","volume":"271","author":"Wheelock","year":"1964","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110477_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112305","article-title":"Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting","volume":"136","author":"Wu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.virol.2025.110477_bib61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1472-6750-4-21","article-title":"A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods","volume":"4","author":"Yarrow","year":"2004","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.virol.2025.110477_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195425","article-title":"Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model","volume":"13","author":"Yurchenko","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2025.110477_bib63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/fmb.12.4","article-title":"Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions","volume":"7","author":"Zamarin","year":"2012","journal-title":"Future Microbiol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682225000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682225000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:59:24Z","timestamp":1762221564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682225000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":63,"alternative-id":["S0042682225000893"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2025.110477","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of an apoptotic lentogenic Newcastle disease virus strain by incorporating the p30 protein of African swine fever virus","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2025.110477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110477"}}